This HTML5 document contains 108 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
n9	http://dx.doi.org/10.1016/
schema	http://schema.org/
rdfs	http://www.w3.org/2000/01/rdf-schema#
skos	http://www.w3.org/2004/02/skos/core#
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n8	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q38638751

rdf:type

wikibase:Item

schema:description

artikull shkencor artykuł naukowy article scientifique artigo científico scientific article published on 03 August 2017 2017年論文 wetenschappelijk artikel vetenskaplig artikel 2017年論文 مقالة علمية نشرت في 03 أغسطس 2017 vedecký článok 2017年论文 tudományos cikk teaduslik artikkel 2017 nî lūn-bûn 2017年论文 scienca artikolo articolo scientifico artigo científico scientific article published on 03 August 2017 บทความทางวิทยาศาสตร์ 2017年論文 2017년 논문 научная статья מאמר מדעי επιστημονικό άρθρο 2017年論文 мақолаи илмӣ videnskabelig artikel სამეცნიერო სტატია 2017年论文 vitenskapelig artikkel наукова стаття, опублікована в серпні 2017 artikulong pang-agham bilimsel makale article scientific artículo científico bài báo khoa học বৈজ্ঞানিক নিবন্ধ naučni članak artigo científico article científic scientific article published on 03 August 2017 articol științific 2017年论文 wissenschaftlicher Artikel научни чланак tieteellinen artikkeli artikel ilmiah 2017年論文 2017年论文 научна статия vitskapeleg artikkel artículu científicu espublizáu en 2017 2017年の論文 2017年论文 научни чланак vědecký článek

p:P577

wds:Q38638751-906FAE66-2A85-497A-995D-F4C096F5BFCC

wdt:P577

2017-08-04T00:00:00Z

p:P2093

wds:Q38638751-168A6341-5EF5-45DB-BE10-AA70D5EB0D27 wds:Q38638751-15B604F2-3767-49A1-B1F5-044981EF5860 wds:Q38638751-22120367-92F7-4E1A-86F2-05778FE94B73 wds:Q38638751-38E0A56B-A616-47D4-AF3E-FEB6B4FE553F wds:Q38638751-71ED645C-E1FF-44F2-BB9E-A6D02602D07F wds:Q38638751-61C792D8-EF7B-4323-9E5E-753902226B75 wds:Q38638751-A0D2A267-1D5D-49C1-826E-AE1BE2FE290C wds:Q38638751-8E005842-D61C-4926-ABFF-6982A0AC527D

wdt:P2093

S Culine P Sfumato K Fizazi F Joly M Habibian S Oudard P Marino G Gravis

rdfs:label

Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.

skos:prefLabel

Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.

schema:name

Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.

p:P50

wds:Q38638751-60E087A8-7FC7-4BFE-B53F-488FF3011E3A

wdt:P50

wd:Q59200097

p:P1476

wds:Q38638751-4E05517F-C3A2-4066-B1AE-508379AAE7A6

wdt:P1476

Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial

p:P304

wds:Q38638751-E8BE4CA5-3B13-442B-B0E7-DF5EFDC8D123

wdt:P304

27-33

p:P31

wds:Q38638751-3FC013C8-442F-44D0-B2A7-803326772CD8

wdt:P31

wd:Q13442814

p:P921

wds:Q38638751-EBF520AA-747E-419A-9E6C-A52C496BB754 wds:Q38638751-0ACAA3A7-3E3F-4867-A155-AA9A34CF1590

wdt:P921

wd:Q420436 wd:Q42824827

p:P698

wds:Q38638751-A6804DC3-DB3C-4102-BD4E-CFB6A41BCB3F

wdtn:P698

n8:28780479

wdt:P698

28780479

p:P1433

wds:Q38638751-6DFA78BC-D120-47F8-ADC4-48962E52FFA2

wdt:P1433

wd:Q332260

p:P478

wds:Q38638751-DA1D6E54-C649-413A-99F1-A054FC8D66F4

wdt:P478

84

p:P356

wds:Q38638751-217168C2-C3C9-416F-BED3-41AC94A89861

wdtn:P356

n9:J.EJCA.2017.07.008

wdt:P356

10.1016/J.EJCA.2017.07.008